![](https://www.diabetesnews.com/wp-content/uploads/2012/10/199845-pill_bottle_and_pills_large-150x150.jpg)
Eli Lilly and Co and Boehringer Ingelheim said on Monday that an experimental treatment for type 2 diabetes, empagliflozin, met the primary goal of significantly lowering blood sugar levels in four late-stage trials.
Read more
Eli Lilly and Co and Boehringer Ingelheim said on Monday that an experimental treatment for type 2 diabetes, empagliflozin, met the primary goal of significantly lowering blood sugar levels in four late-stage trials.
Read more